



**RESULTADOS DO INQUÉRITO:
OS EFEITOS DO USO
MSTR®
(LIBERAÇÃO DE TECIDO CICATRIZANTE DE McLOUGHLIN®)
SOBRE A CESÁREA
CICATRIZES**

Realizado a 26 de outubro de 2019

em

A Clínica Newcastle
Avenida 4 Torres, Jesmond,
Newcastle upon Tyne,
NE2 3QE
Reino Unido

COMUNICADO DE IMPRENSA

Tenho o prazer de anunciar os resultados do mais recente estudo de investigação sobre os efeitos do McLoughlin Scar Tissue Release® (MSTR®) nas cicatrizes de cesarianas.

Este segundo projeto de investigação MSTR® foi conduzido na The Newcastle Clinic, Newcastle, Reino Unido, no dia 26 de outubro de 2019 com o radiologista consultor Dr. Peddada Raju MD.

Foi utilizado um scanner de ultrassons General Electric (GE) Soniq S8 para conduzir o teste em nove indivíduos com cicatrizes de cesariana.

Cada sujeito foi pré-digitalizado e as imagens foram gravadas, incluindo:

- Tamanho e profundidade do tecido cicatricial
- A quantidade de vascularização em redor e dentro do tecido cicatricial

O trabalho MSTR® foi então aplicado durante um total de 15 minutos por sujeito, como um único tratamento.

Imediatamente após o tratamento com MSTR®, cada sujeito foi submetido a uma ecografia pós-tratamento conduzida pelo Dr. Raju.

Todos os nove indivíduos apresentaram diminuição do tecido cicatricial no exame pós-tratamento. Um exemplo de melhoria foi uma cicatriz que inicialmente tinha 16,6 mm antes do tratamento. A cicatriz foi novamente medida em apenas 3,6 mm após o tratamento.

Outro exemplo foi o de uma cicatriz longitudinal reduzir o seu tamanho de 18,42 mm antes do tratamento para apenas 8,81 mm depois do tratamento.

Em vários casos, foi observado um aumento da vascularização, não só no tecido circundante, mas também na cicatriz. Curiosamente, é de salientar que em alguns casos NÃO havia vascularização presente na pré-varrimento da mesma área.

Este segundo estudo reconfirma o que foi observado no primeiro estudo de 15 de junho de 2019: o MSTR® não só reduz o tecido cicatricial, como também ajuda a libertar as fibras de colagénio densamente ligadas que compõem o tecido cicatricial para permitir o aumento do fluxo sanguíneo na área novamente.

Pode ler mais sobre o Projeto de Investigação MSTR® aqui:

<https://www.mcloughlin-scar-release.com/research/>

Este segundo projeto de investigação, demonstrando resultados baseados em evidências do método MSTR® de tratamento de tecidos cicatriciais, reforça e confirma a nossa descoberta anterior de junho de 2019 e significa que pode ter ainda mais confiança na fiabilidade e consistência do trabalho do MSTR®.

RESULTADOS DA PESQUISA

Visão geral

Das nove cicatrizes que pesquisámos, sete eram de cesarianas transversais, uma de abdominoplastia e uma de histerectomia abdominal.

Financiamento

Este estudo de investigação foi financiado inteiramente por contribuições públicas e privadas.

Participantes da pesquisa

Os participantes da investigação foram encontrados através de solicitações nas redes sociais.

Os objetivos específicos para a ecografia utilizando a técnica MSTR® são:

- Alterações no tamanho e profundidade do tecido cicatricial
- Alterações do fluxo sanguíneo (vascularidade) nos tecidos adjacentes em redor do tecido cicatricial
- Alterações no fluxo sanguíneo (vascularidade) dentro do próprio tecido cicatricial

A equipa de investigação:

Dr. Peddada Raju - Radiologista Consultor

Paula Esson - Investigadora de ligação, praticante de MSTR® e assistente do Dr. Raju

Silke Lauth - Assistente de investigação, praticante de MSTR®

Alastair McLoughlin - criador do MSTR®, praticante principal

Local:

A Clínica Newcastle

Avenida 4 Torres, Jesmond,

Newcastle upon Tyne,

NE2 3QE

Reino Unido

Hipótese

Devido à crescente evidência de centenas de estudos de caso registados de uma grande variedade de cicatrizes de feridas pós-cirúrgicas e traumáticas que apresentam alterações extremamente boas e consistentes no tecido cicatricial, colocamos a hipótese de que estas alterações se devem à separação da matriz de colagénio fortemente unida e do substrato encontrados em locais de tecido cicatricial utilizando o método MSTR®.

A nossa hipótese é que o fluxo sanguíneo e linfático aumenta através e à volta do local do tecido cicatricial.

As alterações superficiais já observadas na densidade do tecido cicatricial e na fibrose sugerem a possibilidade de as fibras de colagénio dentro do tecido cicatricial serem realinhadas, formando um alinhamento mais natural - como se verifica em tecidos saudáveis não afetados.

Colocámos também a hipótese de que as estruturas fasciais aderidas em redor da cicatriz também são libertadas.

Frequentemente, as alterações sensoriais e a melhoria da transmissão nervosa também são observadas no feedback do estudo de caso.

Temos também evidências de estudos de caso de que os testes de amplitude de movimento indicam uma melhor funcionalidade da coluna vertebral e dos membros. As alterações e a redução da dor lombar, por exemplo, podem ser outro benefício do tratamento da cesariana.

Método

- Realizamos o estudo de investigação em nove sujeitos.
- Foi utilizado um questionário do doente para recolher informações gerais sobre o doente. Incluímos também questões específicas sobre a cesariana em si: quando ocorreu a cirurgia, quaisquer efeitos físicos produzidos pela cicatriz e quaisquer efeitos emocionais ou psicológicos que possam ser sentidos por causa da cicatriz.
- Uma ecografia pré-tratamento foi realizada pelo Dr. Peddada Raju. As imagens foram captadas pelo scanner de ecografia GE Soniq S8. Medidas do tecido cicatricial também foram registadas.
- O tratamento MSTR® foi realizado na cicatriz abdominal durante 15 minutos no total. Durante o tratamento de 15 minutos, foram incluídos dois intervalos de dois minutos cada. Isto reduziu o tempo real do tratamento MSTR® para aproximadamente 11 minutos de aplicação prática no total.
- Foi registada uma ecografia pós-tratamento e medições de tecido cicatricial conduzidas pelo Dr. Raju.

Resultados










ID DO ASSUNTO	DD	LF	NC	Educação Física	CW	Sobre	KH	JC	SS
Idade	46 anos. 7 meses.	37 anos. 3 meses.	49 anos. 1 mês.	49 anos. 9 meses.	50 anos. 3 meses.	53 anos. 5 meses.	42 anos. 1 mês.	36 anos. 5 meses.	33 anos. 7 meses.
Número de C - secções	2	1	1 abdominal histerectomia	1	2	3	1	1 abdómen plastia	1
Era de C-secções	13 anos + 11 anos	5 meses	3 anos	23 anos	20 anos + 18 anos	21 anos, 18 anos, 17 anos	3 anos	1 ano	1 ano
Tipo Emergência = E Planeado = P	E+P	P	P	E	P+E	E+P+P	E	P	P
Valores:									
Pré tx Mais profundo	19,3 mm	14,21 mm	11,35 mm	*	19,15 mm	17,12 mm	7,05 mm	10,14 mm	9,3 mm
Pós tx Mais profundo	10,7 mm	7,26 mm	9,95 mm	*	14,29 mm	15,79 mm	5,88 mm	7,85 mm	7,56 mm
Pré tx Longitudinal	9,4 mm	10,03 mm	6,73 mm	18,42 mm	15,14 mm	14,28 mm	11,05 mm	8,08 mm	5,34 mm
Pós tx Longitudinal	6,7 mm	5,28 mm	6,55 mm	8,81 mm	8,4 mm	8,25 mm	10,77 mm	7,62 mm	4,86 mm
Pré tx Profundo	16,6 mm	11,95 mm	11,22 mm	*	16,14 mm	10,99 mm	5,6 mm	7,78 mm	6,6 mm
Pós tx Profundo	3,6 mm	5,11 mm	5,13 mm	*	10,62 mm	9,0 mm	3,6 mm	7,14 mm	4,39 mm
Pré tx Transversal	9,9 mm	9,72 mm	7,2 mm	14,97 mm	12,78 mm	13,52 mm	8,95 mm	5,84 mm	3,36 mm**
Pós tx Transversal	7,3 mm	5,71 mm	4,65 mm	11,34 mm	8,58 mm	11,77 mm	6,36 mm	4,02 mm	5,7 mm**

* = Não foi possível fazer medições precisas nestas áreas.

* * = Uma leitura aparentemente anômala onde o tecido cicatricial parecia aumentar. A medição pós-tratamento foi verificada três vezes pelo Dr. Raju para garantir a precisão. Após consulta com o Dr. Raju, concluímos que um aumento do fluido linfático na área pode ter sido responsável pelo tamanho aparente da cicatriz. Na imagem da ecografia pode ver duas pequenas áreas pretas (fluido) pré-tratamento, que desapareceram na imagem pós-tratamento.







MEDIDAS TOTAIS DA CICATRIZ E PERCENTAGEM DE ALTERAÇÃO:










	Pré-tratamento	Pós-tratamento	Redução percentual
mais profundo	107,62 mm	79,28 mm	26,33%
longitudinal	98,47 mm	67,24 mm	31,72%
profundo	86,88 mm	48,59 mm	44,07%
transversal	86,24 mm	65,7 mm	23,82%
Medidas totais	379,21 mm	260,81 mm	31,22%

Assunto DD	Pré-tratamento	Pós-tratamento
mais profundo	NEWCASTLE CLINIC 26/10/19 09:40:24 PPJ DD261019, 20/03/73 MI 1.0 Tis 0.5 ML6-15 MSK Gen CAESAREAN SCAR DEEPEST  1 L 19.30 mm FR 16 AO% 100 CHI Frq 12.0 Gn 46 S/A 3/3 Map F/0 D 5.0 DR 69 2- II II 4-	NEWCASTLE CLINIC 26/10/19 10:06:42 PPJ DD261019, 20/03/73 MI 1.0 Tis 0.5 ML6-15 MSK Gen CAESAREAN SCAR POST TREATMENT DEEPEST  1 L 10.70 mm FR 16 AO% 100 CHI Frq 12.0 Gn 46 S/A 3/3 Map F/0 D 5.0 DR 69 2- II II 4-
longitudinal	NEWCASTLE CLINIC 26/10/19 09:42:55 PPJ DD261019, 20/03/73 MI 1.0 Tis 0.5 ML6-15 MSK Gen CAESAREAN SCAR  1 L 9.90 mm FR 16 AO% 100 CHI Frq 12.0 Gn 46 S/A 3/3 Map F/0 D 5.0 DR 69 2- II II 4-	NEWCASTLE CLINIC 26/10/19 10:10:14 PPJ DD261019, 20/03/73 MI 1.0 Tis 0.5 ML6-15 MSK Gen CAESAREAN SCAR POST TREATMENT  1 L 6.70 mm FR 16 AO% 100 CHI Frq 12.0 Gn 46 S/A 3/3 Map F/0 D 5.0 DR 69 2- II II 4-
profundo	NEWCASTLE CLINIC 26/10/19 09:41:25 PPJ DD261019, 20/03/73 MI 1.0 Tis 0.5 ML6-15 MSK Gen CAESAREAN SCAR DEEP  1 L 16.60 mm FR 16 AO% 100 CHI Frq 12.0 Gn 46 S/A 3/3 Map F/0 D 5.0 DR 69 2- II II 4-	NEWCASTLE CLINIC 26/10/19 10:07:45 PPJ DD261019, 20/03/73 MI 1.0 Tis 0.5 ML6-15 MSK Gen CAESAREAN SCAR POST TREATMENT DEEP  1 L 3.60 mm FR 16 AO% 100 CHI Frq 12.0 Gn 46 S/A 3/3 Map F/0 D 5.0 DR 69 2- II II 4-
transversal	NEWCASTLE CLINIC 26/10/19 09:46:29 PPJ DD261019, 20/03/73 MI 1.0 Tis 0.5 ML6-15 MSK Gen CAESAREAN SCAR  1 L 9.90 mm FR 16 AO% 100 CHI Frq 12.0 Gn 46 S/A 3/3 Map F/0 D 5.0 DR 69 2- II II 4-	NEWCASTLE CLINIC 26/10/19 10:09:30 PPJ DD261019, 20/03/73 MI 1.0 Tis 0.5 ML6-15 MSK Gen CAESAREAN SCAR POST TREATMENT  1 L 7.30 mm FR 16 AO% 100 CHI Frq 12.0 Gn 46 S/A 3/3 Map F/0 D 5.0 DR 69 2- II II 4-
vascularidade	NEWCASTLE CLINIC 26/10/19 09:46:29 PPJ DD261019, 20/03/73 MI 0.8 Tis 1.0 ML6-15 MSK Gen CAESAREAN SCAR  FR 3 AO% 100 CHI Frq 12.0 Gn 46 D 7.0 2- PDI Frq 7.7 Gn 28.0 L/A 2/5 PRF 1.0 WF 131 S/P 1/16 II II 4- 6-	NEWCASTLE CLINIC 26/10/19 10:14:16 PPJ DD261019, 20/03/73 MI 0.8 Tis 0.9 ML6-15 MSK Gen CAESAREAN SCAR POST TREATMENT  FR 4 AO% 100 CHI Frq 12.0 Gn 46 D 5.0 2- PDI Frq 7.7 Gn 24.0 L/A 2/5 PRF 0.4 WF 52 S/P 1/16 II II 4-

Assunto LF	Pré-tratamento	Pós-tratamento
mais profundo		
longitudinal		
profundo		
transversal		
vascularidade		











Assunto NC	Pré-tratamento	Pós-tratamento
mais profundo	NEWCASTLE CLINIC 26/10/19 10:22:48 PPJ NC120970, 12/09/70 MI 1.1 Tis 0.1 ML6-15 MSK Gen HYSTERECTOMY SCAR DEEPEST 1 L 11.35 mm	NEWCASTLE CLINIC 26/10/19 10:49:52 PPJ NC120970, 12/09/70 MI 1.2 Tis 0.1 ML6-15 MSK Gen HYSTERECTOMY SCAR POST TREATMENT 1 L 9.95 mm
longitudinal	NEWCASTLE CLINIC 26/10/19 10:24:45 PPJ NC120970, 12/09/70 MI 1.1 Tis 0.1 ML6-15 MSK Gen HYSTERECTOMY SCAR LONG 1 L 7.20 mm	NEWCASTLE CLINIC 26/10/19 10:52:47 PPJ NC120970, 12/09/70 MI 1.2 Tis 0.1 ML6-15 MSK Gen HYSTERECTOMY SCAR POST TREATMENT 1 L 4.65 mm
profundo	NEWCASTLE CLINIC 26/10/19 10:23:29 PPJ NC120970, 12/09/70 MI 1.1 Tis 0.1 ML6-15 MSK Gen HYSTERECTOMY SCAR DEEP 1 L 11.22 mm	NEWCASTLE CLINIC 26/10/19 10:52:01 PPJ NC120970, 12/09/70 MI 1.2 Tis 0.1 ML6-15 MSK Gen HYSTERECTOMY SCAR POST TREATMENT 1 L 5.13 mm
transversal	NEWCASTLE CLINIC 26/10/19 10:24:45 PPJ NC120970, 12/09/70 MI 1.1 Tis 0.1 ML6-15 MSK Gen HYSTERECTOMY SCAR TRANV 1 L 7.20 mm	NEWCASTLE CLINIC 26/10/19 10:52:47 PPJ NC120970, 12/09/70 MI 1.2 Tis 0.1 ML6-15 MSK Gen HYSTERECTOMY SCAR POST TREATMENT 1 L 4.65 mm
vascularidade	NEWCASTLE CLINIC 26/10/19 10:28:10 PPJ NC120970, 12/09/70 MI 1.0 Tis 0.8 ML6-15 MSK Gen HYSTERECTOMY SCAR VASC	NEWCASTLE CLINIC 26/10/19 10:55:11 PPJ NC120970, 12/09/70 MI 1.1 Tis 0.8 ML6-15 MSK Gen HYSTERECTOMY SCAR POST TREATMENT

Assunto Educação Física	Pré-tratamento	Pós-tratamento
mais profundo	NENHUMA IMAGEM GRAVADA	NENHUMA IMAGEM GRAVADA
longitudinal	 NEWCASTLE CLINIC 26/10/19 11:16:33 PPJ PE170170, 17/01/70 MI 1.1 TIs 0.1 ML6-15 MSK Gen CAESAREAN SECTION SCAR LOGIO S8 1 L 18.42 mm FR 20 AO% 100 CHI Frq 12.0 Gn 46 S/A 3/3 Map F/0 D 3.5 1- DR 69 2- 3-	 NEWCASTLE CLINIC 26/10/19 11:27:57 PPJ PE170170, 17/01/70 MI 1.0 TIs 0.9 ML6-15 MSK Gen CAESAREAN SECTION SCAR LOGIO S8 1 L 8.81 mm FR 6 AO% 100 CHI Frq 12.0 Gn 46 D 3.5 1- PDI Frq 7.7 Gn 25.0 L/A 2/5 PRF 1.0 WF 131 S/P 1/16 2- 3-
profundo	NENHUMA IMAGEM GRAVADA	NENHUMA IMAGEM GRAVADA
transversal	 NEWCASTLE CLINIC 26/10/19 11:16:53 PPJ PE170170, 17/01/70 MI 1.1 TIs 0.1 ML6-15 MSK Gen CAESAREAN SECTION SCAR LOGIO S8 1 L 14.97 mm FR 20 AO% 100 CHI Frq 12.0 Gn 46 S/A 3/3 Map F/0 D 3.5 1- DR 69 2- 3-	 NEWCASTLE CLINIC 26/10/19 11:28:45 PPJ PE170170, 17/01/70 MI 1.0 TIs 0.9 ML6-15 MSK Gen CAESAREAN SECTION SCAR LOGIO S8 1 L 11.34 mm FR 6 AO% 100 CHI Frq 12.0 Gn 46 D 3.5 1- PDI Frq 7.7 Gn 25.0 L/A 2/5 PRF 1.0 WF 131 S/P 1/16 2- 3-
vascularidade	 NEWCASTLE CLINIC 26/10/19 11:17:35 PPJ PE170170, 17/01/70 MI 1.0 TIs 0.9 ML6-15 MSK Gen CAESAREAN SECTION SCAR LOGIO S8 1 L 14.97 mm FR 6 AO% 100 CHI Frq 12.0 Gn 46 D 3.5 1- PDI Frq 7.7 Gn 25.0 L/A 2/5 PRF 1.0 WF 131 S/P 1/16 2- 3-	 NEWCASTLE CLINIC 26/10/19 11:29:08 PPJ PE170170, 17/01/70 MI 1.0 TIs 0.9 ML6-15 MSK Gen CAESAREAN SECTION SCAR LOGIO S8 1 L 11.34 mm FR 6 AO% 100 CHI Frq 12.0 Gn 46 D 3.5 1- PDI Frq 7.7 Gn 25.0 L/A 2/5 PRF 1.0 WF 131 S/P 1/16 2- 3-

Assunto CW	Pré-tratamento	Pós-tratamento
mais profundo	NEWCASTLE CLINIC 26/10/19 11:38:07 PPJ CW200769, 20/07/69 MI 1.2 TIs 0.1 ML6-15 MSK Gen FR 21 AO% 100 CAESAREAN SECTION  1 L 19.15 mm	NEWCASTLE CLINIC 26/10/19 12:06:23 PPJ CW200769, 20/07/69 MI 1.2 TIs 0.1 ML6-15 MSK Gen FR 21 AO% 100 CAESAREAN SECTION POST TREATMENT  1 L 14.29 mm
longitudinal	NEWCASTLE CLINIC 26/10/19 11:38:44 PPJ CW200769, 20/07/69 MI 1.2 TIs 0.1 ML6-15 MSK Gen FR 21 AO% 100 CAESAREAN SECTION  1 L 15.14 mm	NEWCASTLE CLINIC 26/10/19 12:08:49 PPJ CW200769, 20/07/69 MI 1.2 TIs 0.1 ML6-15 MSK Gen FR 21 AO% 100 CAESAREAN SECTION POST TREATMENT  1 L 8.40 mm
profundo	NEWCASTLE CLINIC 26/10/19 11:38:44 PPJ CW200769, 20/07/69 MI 1.2 TIs 0.1 ML6-15 MSK Gen FR 21 AO% 100 CAESAREAN SECTION  1 L 16.14 mm	NEWCASTLE CLINIC 26/10/19 12:08:05 PPJ CW200769, 20/07/69 MI 1.2 TIs 0.1 ML6-15 MSK Gen FR 21 AO% 100 CAESAREAN SECTION POST TREATMENT  1 L 10.62 mm
transversal	NEWCASTLE CLINIC 26/10/19 11:40:12 PPJ CW200769, 20/07/69 MI 1.2 TIs 0.1 ML6-15 MSK Gen FR 21 AO% 100 CAESAREAN SECTION  1 L 12.78 mm	NEWCASTLE CLINIC 26/10/19 12:08:36 PPJ CW200769, 20/07/69 MI 1.2 TIs 0.1 ML6-15 MSK Gen FR 21 AO% 100 CAESAREAN SECTION POST TREATMENT  1 L 8.58 mm
vascularidade	NEWCASTLE CLINIC 26/10/19 11:41:35 PPJ CW200769, 20/07/69 MI 1.1 TIs 0.8 ML6-15 MSK Gen FR 9 AO% 100 CAESAREAN SECTION  1 L 12.78 mm	NEWCASTLE CLINIC 26/10/19 12:11:58 PPJ CW200769, 20/07/69 MI 1.1 TIs 0.8 ML6-15 MSK Gen FR 8 AO% 100 CAESAREAN SECTION POST TREATMENT  1 L 8.58 mm

Assunto AB	Pré-tratamento	Pós-tratamento
mais profundo	NEWCASTLE CLINIC 26/10/19 11:58:28 PPJ AB1210566, 12/05/66 MI 1.1 Tis 0.1 ML6-15 MSK Gen CAESAREAN SECTION SCAR 1 L 17.12 mm FR 20 AO% 100 CHI Frq 12.0 Gn 46 S/A 3/3 Map F/0 D 3.5 DR 69	NEWCASTLE CLINIC 26/10/19 12:24:54 PPJ AB1210566, 12/05/66 MI 1.2 Tis 0.1 ML6-15 MSK Gen SCAR POST TREATMENT 1 L 15.79 mm FR 21 AO% 100 CHI Frq 12.0 Gn 46 S/A 3/3 Map F/0 D 3.0 DR 69
longitudinal	NEWCASTLE CLINIC 26/10/19 12:00:43 PPJ AB1210566, 12/05/66 MI 1.1 Tis 0.1 ML6-15 MSK Gen CAESAREAN SECTION SCAR 1 L 14.28 mm FR 20 AO% 100 CHI Frq 12.0 Gn 46 S/A 3/3 Map F/0 D 3.5 DR 69	NEWCASTLE CLINIC 26/10/19 12:27:31 PPJ AB1210566, 12/05/66 MI 1.2 Tis 0.1 ML6-15 MSK Gen SCAR POST TREATMENT 1 L 8.25 mm FR 21 AO% 100 CHI Frq 12.0 Gn 46 S/A 3/3 Map F/0 D 3.0 DR 69
profundo	NEWCASTLE CLINIC 26/10/19 11:59:41 PPJ AB1210566, 12/05/66 MI 1.1 Tis 0.1 ML6-15 MSK Gen CAESAREAN SECTION SCAR 1 L 10.99 mm FR 20 AO% 100 CHI Frq 12.0 Gn 46 S/A 3/3 Map F/0 D 3.5 DR 69	NEWCASTLE CLINIC 26/10/19 12:26:16 PPJ AB1210566, 12/05/66 MI 1.2 Tis 0.1 ML6-15 MSK Gen SCAR POST TREATMENT 1 L 9.00 mm FR 21 AO% 100 CHI Frq 12.0 Gn 46 S/A 3/3 Map F/0 D 3.0 DR 69
transversal	NEWCASTLE CLINIC 26/10/19 12:00:15 PPJ AB1210566, 12/05/66 MI 1.1 Tis 0.1 ML6-15 MSK Gen CAESAREAN SECTION SCAR 1 L 13.52 mm FR 20 AO% 100 CHI Frq 12.0 Gn 46 S/A 3/3 Map F/0 D 3.5 DR 69	NEWCASTLE CLINIC 26/10/19 12:26:58 PPJ AB1210566, 12/05/66 MI 1.2 Tis 0.1 ML6-15 MSK Gen SCAR POST TREATMENT 1 L 11.77 mm FR 21 AO% 100 CHI Frq 12.0 Gn 46 S/A 3/3 Map F/0 D 3.0 DR 69
vascularidade	NEWCASTLE CLINIC 26/10/19 12:02:10 PPJ AB1210566, 12/05/66 MI 1.0 Tis 0.9 ML6-15 MSK Gen CAESAREAN SECTION SCAR 1 L 13.52 mm FR 7 AO% 100 CHI Frq 12.0 Gn 46 D 3.5 PDI Frq 7.7 Gn 25.0 L/A 2/5 PRF 1.0 WF 131 S/P 1/16	NEWCASTLE CLINIC 26/10/19 12:28:26 PPJ AB1210566, 12/05/66 MI 1.1 Tis 0.8 ML6-15 MSK Gen SCAR POST TREATMENT 1 L 11.77 mm FR 8 AO% 100 CHI Frq 12.0 Gn 46 D 3.0 PDI Frq 7.7 Gn 25.0 L/A 2/5 PRF 1.0 WF 131 S/P 1/16

Assunto KH	Pré-tratamento	Pós-tratamento
mais profundo	NEWCASTLE CLINIC 26/10/19 13:45:13 PPJ KH100977, 10/09/77 MI 1.2 TIs 0.1 ML6-15 MSK Gen CAESAREAN SECTION SCAR 1 L 7.05 mm CHI Frq 12.0 Gn 46 S/A 3/3 Map F/0 D 2.5 DR 69	NEWCASTLE CLINIC 26/10/19 14:14:47 PPJ KH100977, 10/09/77 MI 1.2 TIs 0.1 ML6-15 MSK Gen POST TREATMENT SCAR 1 L 5.88 mm CHI Frq 12.0 Gn 46 S/A 3/3 Map F/0 D 3.0 DR 69
longitudinal	NEWCASTLE CLINIC 26/10/19 13:49:36 PPJ KH100977, 10/09/77 MI 1.2 TIs 0.1 ML6-15 MSK Gen CAESAREAN SECTION SCAR 1 L 11.05 mm CHI Frq 12.0 Gn 46 S/A 3/3 Map F/0 D 2.5 DR 69	NEWCASTLE CLINIC 26/10/19 14:16:07 PPJ KH100977, 10/09/77 MI 1.2 TIs 0.1 ML6-15 MSK Gen POST TREATMENT SCAR 1 L 10.77 mm CHI Frq 12.0 Gn 46 S/A 3/3 Map F/0 D 3.0 DR 69
profundo	NEWCASTLE CLINIC 26/10/19 13:46:08 PPJ KH100977, 10/09/77 MI 1.2 TIs 0.1 ML6-15 MSK Gen CAESAREAN SECTION SCAR 1 L 5.60 mm CHI Frq 12.0 Gn 46 S/A 3/3 Map F/0 D 2.5 DR 69	NEWCASTLE CLINIC 26/10/19 14:15:10 PPJ KH100977, 10/09/77 MI 1.2 TIs 0.1 ML6-15 MSK Gen POST TREATMENT SCAR 1 L 3.60 mm CHI Frq 12.0 Gn 46 S/A 3/3 Map F/0 D 3.0 DR 69
transversal	NEWCASTLE CLINIC 26/10/19 13:49:54 PPJ KH100977, 10/09/77 MI 1.2 TIs 0.1 ML6-15 MSK Gen CAESAREAN SECTION SCAR 1 L 8.95 mm CHI Frq 12.0 Gn 46 S/A 3/3 Map F/0 D 2.5 DR 69	NEWCASTLE CLINIC 26/10/19 14:15:36 PPJ KH100977, 10/09/77 MI 1.2 TIs 0.1 ML6-15 MSK Gen POST TREATMENT SCAR 1 L 6.36 mm CHI Frq 12.0 Gn 46 S/A 3/3 Map F/0 D 3.0 DR 69
vascularidade	NEWCASTLE CLINIC 26/10/19 13:50:40 PPJ KH100977, 10/09/77 MI 1.1 TIs 0.8 ML6-15 MSK Gen CAESAREAN SECTION SCAR CHI Frq 12.0 Gn 46 D 2.5 PDI Frq 7.7 Gn 25.0 L/A 2/5 PRF 1.0 WF 131 S/P 1/16	NEWCASTLE CLINIC 26/10/19 14:19:04 PPJ KH100977, 10/09/77 MI 1.1 TIs 0.8 ML6-15 MSK Gen POST TREATMENT SCAR CHI Frq 12.0 Gn 46 D 3.0 PDI Frq 7.7 Gn 25.0 L/A 2/5 PRF 1.0 WF 131 S/P 1/16

Assunto JC	Pré-tratamento	Pós-tratamento
mais profundo		
longitudinal		
profundo		
transversal		
vascularidade		

Assunto SS	Pré-tratamento	Pós-tratamento
mais profundo		
longitudinal		
profundo		
transversal		
vascularidade		

Comprimento total de todas as cicatrizes medidas antes do tratamento = 379,21 mm

Comprimento total de todas as cicatrizes medidas após o tratamento = 260,81 mm

Redução total em todo o tecido cicatricial medido = 31,22%

Conclusão

Após um único tratamento de 15 minutos com MSTR® por sujeito e uma nova varredura imediata da área, verificou-se uma redução observável na quantidade de tecido cicatricial medida nos nove sujeitos.

A redução total do tecido cicatricial é calculada em 31,22%, o que é uma melhoria significativa e demonstra que o MSTR® reduz o tecido cicatricial num único tratamento.

Os resultados desta pesquisa reforçam também as descobertas de pesquisas anteriores (junho de 2019), onde a redução total de cicatrizes foi medida em 33,55%. Este segundo estudo demonstra agora as taxas de resposta do tecido cicatricial consistentemente elevadas e fiáveis com o tratamento MSTR®.

Alastair McLoughlin
www.McLoughlin-Scar-Release.com

© Alastair McLoughlin

Seguem-se os relatórios da The Newcastle Clinic, elaborados pelo Dr. Peddada Raju da The Newcastle Clinic - Reino Unido, datados de 30 de outubro de 2019.

Ref: PPJR/SR

Scan Date: 26.10.19

30th October 2019



Mr Alastair McLoughlin

Germany

Dear Mr McLoughlin

Re: D D DOB: 20.03.73

Ultrasound Examination – Anterior abdominal wall

Clinical Details: History of caesarean section scar in the lower abdominal wall.

Report: The anterior abdominal wall scar in the subcutaneous fat was barely visible and was difficult to measure. The approximate deepest dimension of the scar before treatment is 19.3mm but after the treatment decreased to 10.7mm.

The approximate depth of the scar which was measured just right of the midline (right lateral) was approximately 16.6mm before treatment but after treatment the approximate depth just right of midline decreased to approximately 3.6mm.

The approximate dimensions of the scar in longitudinal and transverse dimensions is 9.4mm x 9.9mm respectively before treatment but following treatment the scar tissue measures approximately 6.7mm x 7.3mm in maximum approximate longitudinal and transverse dimensions respectively.

There was no evidence of any vascularity noted in the scar or around the scar before treatment but following treatment, blood supply around the scar was noted especially in the subcutaneous adipose tissue but there was no evidence of any vascularity noted in the scar following treatment.

Yours sincerely

Dr. P P J Raju
Consultant Radiologist

Newcastle Clinic Limited
4 Towers Avenue
Jesmond
Newcastle Upon Tyne
NE2 3QE

t: 0191 281 2636
f: 0191 281 2393

reception@newcastleclinic.co.uk

Registered by the Care Quality Commission No: NO10000008


Company Registration Number: 5843596

Registered Office: Oakapple House, 1 John Charles Way, Leeds, LS12 6QA

Ref: PPJR/SR

Scan Date: 26.10.19

30th October 2019



Mr Alastair McLoughlin

Germany

Dear Mr McLoughlin

Re: P E DOB: 17.01.70

Ultrasound Examination – Anterior abdominal wall

Clinical Details: Caesarean section noted.

Report: On ultrasound examination, scar tissue measures approximately 18.4mm x 14.9mm in maximum approximate longitudinal and transverse dimensions respectively before treatment but following treatment, there was a decrease in the dimensions of the scar tissue. The scar tissue measures approximately 8.8mm x 11.3mm in maximum longitudinal and transverse dimensions respectively.

Before treatment, there was no evidence of any vascularity noted in and around the scar but following treatment, there was vascularity noted around the scar in the anterior fascia covering the anterior aspect of the rectus abdominus muscle.

Yours sincerely

Dr. P P J Raju
Consultant Radiologist

Newcastle Clinic Limited
4 Towers Avenue
Jesmond
Newcastle Upon Tyne
NE2 3QE
t: 0191 281 2636
f: 0191 281 2393
reception@newcastleclinic.co.uk

Registered by the Care Quality Commission No: NO1000008
Company Registration Number: 5843596
Registered Office: Oakapple House, 1 John Charles Way, Leeds, LS12 6QA

Ref: PPJR/SR

Scan Date: 26.10.19

30th October 2019



Mr Alastair McLoughlin

Germany

Dear Mr McLoughlin

Re: C W DOB: 20.07.69

Ultrasound Examination – Anterior abdominal wall

Clinical Details: Caesarean section noted.

Report: There is evidence of lower abdominal wall caesarean section scar. The deepest dimensions of the anterior abdominal wall scar in the region of the caesarean section measures approximately 19.5mm before treatment but following treatment, the deepest dimension of the scar decreased to approximately 14.2mm only. The approximate depth of the scar before treatment was 16.1mm especially to the right of the midline but following treatment, the approximate depth of the scar decreased to 10.6mm. Approximate dimensions of the scar are 15.1mm x 12.7mm in maximum longitudinal and transverse dimensions respectively before treatment but following treatment, the approximate dimensions of the scar are 8.4mm x 8.5mm in maximum longitudinal and transverse dimensions respectively. On power Doppler interrogation there was minimal vascularity noted around the scar, but no evidence of any vascularity in the scar tissue. Following treatment, there was increase in the vascularity around the scar tissue but again, no evidence of any abnormal vascularity noted in the scar tissue following treatment.

Yours sincerely

Dr. P P J Raju
Consultant Radiologist

Newcastle Clinic Limited
4 Towers Avenue
Jesmond
Newcastle Upon Tyne
NE2 3QE

t: 0191 281 2636
f: 0191 281 2393

reception@newcastleclinic.co.uk

Registered by the Care Quality Commission No: NO10000008


Company Registration Number: 5843596

Registered Office: Oakapple House, 1 John Charles Way, Leeds, LS12 6QA

Ref: PPJR/SR

Scan Date: 26.10.19

30th October 2019



Mr Alastair McLoughlin

Germany

Dear Mr McLoughlin

Re: A B DOB: 12.05.66

Ultrasound Examination – Anterior abdominal wall

Clinical Details: Caesarean section noted.

Report: There is evidence of healed scar noted in the suprapubic region in the lower abdominal wall related to healed caesarean section scar.

Approximately deepest dimension of the scar before treatment is 17mm which decreased to 15.7mm following treatment. The depth of the scar just right of midline is approximately 10.9mm which decreased to 9mm following treatment.

Approximate dimensions of the scar are 14.2mm x 13.5mm and maximum longitudinal and transverse dimension respectively before treatment but following treatment, the approximate dimensions are 8.2mm x 11mm and maximum longitudinal and transverse dimensions respectively.

There was no evidence of any vascularity noted around the scar before treatment but following treatment, there was evidence of minimal vascularity noted in the scar and around the scar on power Doppler interrogation.

Yours sincerely

Dr. P P J Raju
Consultant Radiologist

Newcastle Clinic Limited
4 Towers Avenue
Jesmond
Newcastle Upon Tyne
NE2 3QE
t: 0191 281 2636
f: 0191 281 2393
reception@newcastleclinic.co.uk

Registered by the Care Quality Commission No: NO10000008
Company Registration Number: 5843596
Registered Office: Oakapple House, 1 John Charles Way, Leeds, LS12 6QA

Ref: PPJR/SR

Scan Date: 26.10.19

30th October 2019

Mr Alastair McLoughlin

Germany

Dear Mr McLoughlin

Re: K H DOB: 10.09.77

Ultrasound Examination – Anterior abdominal wall

Clinical Details: Caesarean section noted.

Report: The deepest dimension of the scar in the midline is approximately 7mm before treatment but following treatment, the deepest dimension of the scar decreased to approximately 5.8mm.

The dimension of the scar especially in its maximum depth just right of midline is approximately 5.6mm before treatment but following treatment, this dimension decreased to approximately 3.6mm.

The approximate dimensions of the scar are 8.9mm x 11mm in maximum transverse and longitudinal dimensions respectively before treatment but following treatment, the approximate dimensions of the scar are 6.3mm x 10.7mm and maximum transverse and longitudinal dimensions respectively.

On power Doppler interrogation, there was no evidence of any vascularity noted in the scar or around the scar but following treatment, there was evidence of vascularity noted around the scar including mildly increased vascularity in the scar itself. Please note that this is a deep fascial scar and there was no evidence of any subcutaneous scar tissue especially in the subcutaneous fat on the ultrasound examination.

Yours sincerely

Dr. P P J Raju
Consultant Radiologist



Newcastle Clinic Limited
4 Towers Avenue
Jesmond
Newcastle Upon Tyne
NE2 3QE
t: 0191 281 2636
f: 0191 281 2393
reception@newcastleclinic.co.uk

Registered by the Care Quality Commission No: NO10000008
Company Registration Number: 5843596
Registered Office: Oakapple House, 1 John Charles Way, Leeds, LS12 6QA

Ref: PPJR/LE

Scan Date: 26.10.19

5th November 2019



Mr Alastair McLoughlin

Germany

Dear Mr McLoughlin

Re: J C D.O.B. 10.05.83

Ultrasound Examination – Anterior abdominal wall

Clinical Details: Tummy Tuck scar noted.

Report: The deepest dimension of the scar is approximately 10 mm before treatment. Treatment and the deepest dimension decreased to approximately 7.8 mm. The approximate dimensions of the scar just right of midline is 7.7 mm in its maximum depth which decreased to approximately 7.1 mm following treatment.

The dimensions of the scar tissue is approximately 8 mm x 5.8 mm in maximum longitudinal and transverse dimensions respectively before treatment.

After treatment, the approximate dimensions of scar are 7.6 mm x 4 mm in maximum longitudinal and transverse dimensions respectively.

Before treatment, there was no evidence of vascularity in the scar tissue and there was no evidence of any vascularity noted around the scar tissue on power Doppler interrogation. Following treatment, there was increased vascularity noted in the scar and around the scar.

Yours sincerely

Dr. P P J Raju
Consultant Radiologist

Newcastle Clinic Limited
4 Towers Avenue
Jesmond
Newcastle Upon Tyne
NE2 3QE

t: 0191 281 2636

f: 0191 281 2393

reception@newcastleclinic.co.uk

Registered by the Care Quality Commission No: NO10000008

Company Registration Number: 5843596

Registered Office: Oakapple House, 1 John Charles Way, Leeds, LS12 6QA

Ref: PPJR/SR

Scan Date: 26.10.19

30th October 2019



Mr Alastair McLoughlin

Germany

Dear Mr McLoughlin

Re: S S DOB: 13.03.86

Ultrasound Examination – Anterior abdominal wall

Clinical Details: Caesarean section noted.

Report: Before treatment, the depressed dimension of the scar tissue is approximately 9.3mm which decreased to approximately 7.5mm following treatment of the scar. The approximate dimensions of the scar just right of midline is 6.3mm before treatment but following treatment, the approximate dimensions of the scar is 4.4mm.

The approximate measurements of the scar is 5.3mm x 3.4mm in maximum longitudinal and transverse dimension respectively following treatment, the approximate dimensions of the scar of 4.8mm x 5.7mm in maximum longitudinal and transverse dimensions respectively.

On power Doppler interrogation, there was no evidence of any vascularity noted in and around the scar but following treatment, there was evidence of vascularity noted around the scar which was essentially noted just superficial and anterior to the scar in the subcutaneous soft tissues.

Yours sincerely

Dr. P P J Raju
Consultant Radiologist

Newcastle Clinic Limited
4 Towers Avenue
Jesmond
Newcastle Upon Tyne
NE2 3QE
t: 0191 281 2636
f: 0191 281 2393
reception@newcastleclinic.co.uk

Registered by the Care Quality Commission No. NO1000008
Company Registration Number: 5843596
Registered Office: Oakapple House, 1 John Charles Way, Leeds, LS12 6QA

